Suma M. Krishnan - 23 Nov 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
President, R&D, Director, 10%+ Owner
Signature
/s/ Suma Krishnan
Issuer symbol
KRYS
Transactions as of
23 Nov 2022
Net transactions value
-$320
Form type
4
Filing time
28 Nov 2022, 17:26:06 UTC
Previous filing
10 Nov 2022
Next filing
20 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale $320 -4 -0% $80.01 1,787,718 23 Nov 2022 By Spouse F1, F2, F3
holding KRYS Common Stock 1,726,440 23 Nov 2022 Direct
holding KRYS Common Stock 90,000 23 Nov 2022 By SMK Trust
holding KRYS Common Stock 50,000 23 Nov 2022 By Krishan Family Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
F2 These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
F3 Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
F4 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.